NEW YORK, Jan. 10, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Agile Therapeutics, Inc. (“Agile Therapeutics”) (NASDAQ:AGRX) between March 9, 2016 and January 3, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information go to:
http://www.zlk.com/pslra/agile-therapeutics-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, Agile Therapeutics made materially false and/or misleading statements and/or failed to disclose that: (a) the Twirla contraceptive patch had an efficacy rating that fell below peer group standards; (b) over half of patients in its “Secure” Phase 3 Study discontinued the study early; and (c) the Twirla patch therefore allegedly had a slight chance of gaining approval by the U.S. Food and Drug Administration.
On January 3, 2017, Agile Therapeutics reported “positive top-line results” for the study, yet reported an efficacy measure that failed to meet the standard set by other approved contraceptive patches. In addition, more than 51% of subjects opted to discontinue the study. Upon this news, shares of Agile Therapeutics fell from a close of $5.70 per share on December 30, 2016, to a close of $2.63 per share on January 4, 2017.
If you suffered a loss in Agile Therapeutics you have until March 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 



